CAMPSIITET Phase I/II/III: An interim clinical study update of RGX-121, an investigational gene therapy for the treatment of neuronopathic mucopolysaccharidosis type II (MPS II)

被引：0
|
作者：
Pisani, Laura [1 ]
Ficicioglu, Can [2 ]
Harmatz, Paul [3 ]
Giugliani, Roberto [4 ]
Rajan, Deepa [5 ]
Hagood, Joseph [1 ]
Fiscella, Michele [1 ]
Yang, Lin [1 ]
Gilmor, Michelle [1 ]
Cho, Yoonjin [1 ]
Mulatya, Caroline [1 ]
Phillips, Dawn [1 ]
Boulos, Nidal [1 ]
Falabella, Paulo [1 ]
机构：
[1] REGENXBIO Inc, Rockville, MD USA
[2] Childrens Hosp Philadelphia, Philadelphia, MD USA
[3] UCSF, Benioff Childrens Hosp Oakland, Oakland, CA USA
[4] Univ Fed Rio Grande do Sul, Dept Genet, Med Genet Serv, HCPA, Porto Alegre, RS, Brazil
[5] Univ Pittsburgh, Pittsburgh, PA USA
来源：
MOLECULAR GENETICS AND METABOLISM | 2024年 / 141卷 / 04期
关键词：
D O I：
10.1016/j.ymgme.2024.108245
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
069
引用
收藏
页数：1
相关论文
共 50 条
  • [1] CAMPSIITET Phase I/II/III: An Interim Clinical Study Update of RGX-121, an Investigational Gene Therapy for the Treatment of Neuronopathic Mucopolysaccharidosis Type II (MPS II)
    Pisani, Laura
    Giugliani, Roberto
    Ficicioglu, Can
    Harmatz, Paul
    Rajan, Deepa
    Hagood, Joseph
    Fiscella, Michele
    Yang, Lin
    Gilmor, Michelle
    Cho, Yoonjin
    Mulatya, Caroline
    Phillips, Dawn
    Boulos, Nidal
    Falabella, Paulo
    MOLECULAR THERAPY, 2024, 32 (04) : 26 - 27
  • [2] CAMPSIITETM phase I/II/III: An interim clinical study update of RGX-121, an investigational gene therapy for the treatment of neuronopathic mucopolysaccharidosis type II (MPS II)
    Harmatz, Paul
    Ficicioglu, Can
    Giugliani, Roberto
    Rajan, Deepa
    Hagood, Joseph
    Fiscella, Michele
    Yang, Lin
    Gilmor, Michelle
    Cho, Yoonjin
    Mulatya, Caroline
    Phillips, Dawn
    Boulos, Nidal
    Falabella, Paulo
    Pisani, Laura
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
  • [3] Audiology assessment of participants in CAMPSIITET, a phase I/II/ III study of RGX-121 in neuronopathic MPS II
    Boulos, Nidal
    Roush, Patricia
    Pjetri, Ariana
    Phillips, Dawn
    Pisani, Laura
    Falabella, Paulo
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
  • [4] RGX-121: AN INVESTIGATIONAL GENE THERAPY FOR THE TREATMENT OF NEURONOPATHIC MUCOPOLYSACCHARIDOSIS TYPE II (MPS II): INTERIM ANALYSIS OF DATA FROM THE FIRST-IN-HUMAN STUDY
    Blair, D. R.
    Harmatz, P.
    Ficicioglu, C.
    Giugliani, R.
    Rajan, D. S.
    Hagood, J.
    Fiscella, M.
    Yang, L.
    Gilmor, M.
    Cho, Y.
    Mulatya, C.
    Phillips, D.
    Falabella, P.
    Pisani, L.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2024, 72 (01) : 638 - 638
  • [5] RGX-121 Gene Therapy for the Treatment of Neuronopathic Mucopolysaccharidosis Type II (MPS II): Interim Analysis of Data from the First in Human Study
    Harmatz, Paul
    Ficicioglu, Can
    Giugliani, Roberto
    Rajan, Deepa
    Hagood, Joseph
    Fiscella, Michele
    Yang, Lin
    Gilmor, Michelle
    Cho, Yoonjin
    Phillips, Dawn
    Pisani, Laura
    Falabella, Paulo
    MOLECULAR THERAPY, 2023, 31 (04) : 398 - 398
  • [6] RGX-121 gene therapy for the treatment of neuronopathic mucopolysaccharidosis type II (MPS II): Interim analysis of data from the first in human study
    Harmatz, Paul
    Ficicioglu, Can H.
    Giugliani, Roberto
    Rajan, Deepa
    Hagood, Joseph
    Fiscella, Michele
    Yang, Lin
    Gilmor, Michelle
    Cho, Yoonjin
    Phillips, Dawn
    Falabella, Paulo
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 57 - 57
  • [7] Audiology assessment of participants in CAMPSIITE®, a phase I/II/ III study of investigational RGX-121 in neuronopathic MPS II
    Boulos, Nidal
    Roush, Patricia A.
    Phillips, Dawn
    Pisani, Laura
    Falabella, Paulo
    MOLECULAR GENETICS AND METABOLISM, 2025, 144 (02) : 13 - 13
  • [8] RGX-121: An Investigational Gene Therapy for the Treatment of Neuronopathic Mucopolysaccharidosis Type II (MPSII): Interim Analysis from the First-in-Human Study
    Pisani, L.
    Ficicioglu, C.
    Giugliani, R.
    Harmatz, P.
    Rajan, D.
    Hagood, J.
    Fiscella, M.
    Yang, L.
    Wang, H.
    Gilmor, M.
    Cho, Y.
    Mulatya, C.
    Phillips, D.
    Falabella, P.
    ANNALS OF NEUROLOGY, 2023, 94 : S67 - S68
  • [9] RGX-121 gene therapy for the treatment of severe mucopolysaccharidosis type II (MPS II): Interim analysis of data from a Phase 1/2 study
    Harmatz, P.
    Giugliani, R.
    Escolar, M.
    Ficicioglu, C.
    Fiscella, M.
    Yang, L.
    Cho, Y.
    Falabella, P.
    ANNALS OF NEUROLOGY, 2022, 92 : S170 - S170
  • [10] RGX-121 gene therapy for severe Mucopolysaccharidosis Type II (MPS II): Interim neurodevelopmental outcomes and biomarker results
    Harmatz, Paul
    Escolar, Maria
    Ficicioglu, Can
    Giugliani, Roberto
    Cho, Yoonjin
    Phillips, Dawn
    Nevoret, Marie-Laure
    Falabella, Paulo
    NEUROLOGY, 2021, 96 (15)
12345